New Adjuvant Treatment for High-Risk Early Breast Cancer
Olaparib (Lynparza) is now approved for the adjuvant treatment of adult patients who have, or are suspected to have, the germline variation of BRCA-mutated human epidermal growth factor receptor 2–negative high-risk early breast cancer and who were previously treated with neoadjuvant or adjuvant chemotherapy.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nursing